Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag Effect on Midazolam PK in Healthy Males
NCT02791815Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of Midazolam and Area Under the Curve (AUC0-inf) of Midazolam. Started Jul 2016; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02791815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791815.